Health CarePharmaceuticals & Biotechnology
  • Price (USD)54.87
  • Today's Change0.000 / 0.00%
  • Shares traded1.53m
  • 1 Year change0.11%
  • Beta1.3507
Data delayed at least 15 minutes, as of Dec 06 2019 23:30 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Cardinal Health, Inc. is a healthcare services and products company. The Company operates through two segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products. This segment also operates nuclear pharmacies and cyclotron facilities; provides pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers, and provides services to healthcare companies. The Medical segment distributes a range of medical, surgical and laboratory products, and provides services to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers. This segment also manufactures, sources and develops its own Cardinal Health brand medical and surgical products. It provides post-acute care management and transition services, and software to hospitals.

  • Revenue in USD (TTM)147.66bn
  • Net income in USD-4.15bn
  • Incorporated1979
  • Employees49.50k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CAH:NYQ since
mscripts LLCDeal completed22 Apr 201922 Apr 2019Deal completed19.28%--
Mirixa CorpDeal completed08 Jan 201908 Jan 2019Deal completed19.80%--
Data delayed at least 15 minutes, as of Dec 06 2019 23:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Ionis Pharmaceuticals Inc821.03m97.71m9.09bn737.0094.176.80108.2711.070.68613.085.829.500.319324.8525.731,114,022.002.72-3.533.21-4.2458.0027.758.52-10.4910.31--0.3048--16.6332.42-154.21--54.38--
Mylan NV11.39bn54.30m9.96bn35.00k184.470.86854.980.87430.10460.091422.0822.210.3532.594.43325,354.300.16842.580.19863.1739.3843.620.47686.640.83572.760.53170.00-3.9810.60-59.01-11.5324.77--
Elanco Animal Health Inc3.08bn93.80m10.10bn5.59k106.011.8425.353.280.25550.25558.3814.710.34191.424.52551,574.301.04--1.17--52.2449.853.04-2.541.674.780.3007--6.159.72125.16-14.65----
Neurocrine Biosciences, Inc.675.57m21.09m10.76bn585.00691.4718.72387.9915.920.16890.16897.166.240.63920.77147.981,154,819.002.00-16.652.74-17.9399.04--3.12-63.616.998.730.4126--179.19174.05114.81--114.61--
EXACT Sciences Corporation723.70m-215.91m12.70bn1.98k--14.96--17.55-1.71-1.715.705.760.44284.0311.66366,059.20-13.21-33.75-16.10-36.9474.3468.50-29.83-97.502.63-10.080.522--70.86155.8726.81--76.69--
Alnylam Pharmaceuticals, Inc.169.10m-821.37m13.80bn1.07k--8.57--81.60-7.76-7.761.6014.440.08020.44336.57158,781.20-38.95-34.42-43.89-37.4991.40---485.73-762.015.22--0.00---16.699.69-55.29--99.59--
BioMarin Pharmaceutical Inc.1.60bn-42.52m14.36bn2.85k--4.67226.418.96-0.2504-0.25048.8917.120.34640.6064.07562,590.10-0.9191-5.98-1.07-6.8478.8881.28-2.65-19.562.53-14.590.2178--13.5222.14-3.30--17.28--
Cardinal Health Inc147.66bn-4.15bn16.05bn49.50k--17.86--0.1087-14.05-14.05495.093.073.7311.2918.152,983,071.00-10.482.60-24.716.024.645.16-2.810.72680.49926.640.898559.416.389.83300.443.225.679.50
AmerisourceBergen Corp.179.59bn818.37m18.17bn22.00k22.956.3413.920.10123.844.02843.5413.924.6715.2014.458,163,
Seattle Genetics, Inc.801.42m-304.29m20.14bn1.30k--11.30--25.13-1.87-1.874.9310.400.43730.80874.68615,531.50-16.60-16.85-18.87-20.5991.5688.47-37.97-31.444.49-4.910.00--35.7619.45-77.40---0.8587--
Incyte Corporation2.11bn404.96m20.35bn1.37k50.688.4044.209.661.861.869.7111.250.735113.018.061,541,896.0014.12-1.9116.70-2.3395.8896.4419.21-2.445.01--0.0205--22.5039.60134.97--76.69--
Data as of Dec 06 2019. Currency figures normalised to Cardinal Health Inc's reporting currency: US Dollar USD

Institutional shareholders

42.05%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 201936.07m12.34%
SSgA Funds Management, Inc.as of 30 Sep 201921.78m7.45%
Macquarie Investment Management Business Trustas of 30 Sep 201915.47m5.29%
BlackRock Fund Advisorsas of 30 Sep 201915.27m5.22%
Mellon Investments Corp.as of 30 Sep 20196.93m2.37%
SunAmerica Asset Management LLCas of 30 Sep 20196.73m2.30%
Invesco Capital Management LLCas of 30 Sep 20195.73m1.96%
Columbia Management Investment Advisers LLCas of 30 Sep 20195.29m1.81%
Fidelity Management & Research Co.as of 30 Sep 20194.86m1.66%
Geode Capital Management LLCas of 30 Sep 20194.83m1.65%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.